# International Antiviral Society-USA

#### **MISSION**

The mission of the International Antiviral Society–USA (IAS–USA) is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research.

#### **ACCREDITATION STATEMENT**

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. **SCIENTIFIC LEADERSHIP BOARD** 

The Scientific Leadership Board guides the needs assessment, design, development, and evaluation of all educational and scientific programming of the organization. Visit https://www.iasusa.org/about/ias-usa-scientific-leadership-bod/ for a list of Scientific Leadership Board members.

#### **IAS-USA GOVERNANCE**

he IAS–USA Governance members provide administrative oversight for the operations and mission of the IAS–USA. Non-Staff Members serve in a volunteer capacity and are not compensated for their roles in oversight and governance of the organization. Visit https://www.iasusa.org/about/ias-usa-governance/for a list of Scientific Leadership Board members.

IMPROVING THE MANAGEMENT OF HIV
DISEASE®: ADVANCED CME COURSES IN HIV
PATHOGENESIS, ANTIRETROVIRALS, AND OTHER
SELECTED ISSUES IN HIV DISEASE
MANAGEMENT (HYBRID IN 2022)

These one-day courses are designed for HIV specialists who are actively involved in HIV disease management or research. The virtual courses are half-day updates that focus on the key issues clinicians are likely facing. Nationally and internationally recognized faculty provide advanced-level presentations with balanced, timely, scientifically rigorous, and clinically relevant information about HIV disease management. Visit

www.iasusa.org/activities/live-courses/hiv-courses/ for more information on upcoming and on-demand CME courses.

### **WEBINARS**

The IAS–USA offers state-of-the-art webinars on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. They are led by nationally and internationally recognized faculty. Each webinar lasts 75 to 90 minutes and provides continuing education credits. Visit

www.iasusa.org/activities/webinars/upcoming-webinars/ for upcoming webinars. On-demand webinars offer CME credit for a year at

www.iasusa.org/activities/webinars/on-demandwebinars/.

Webinar topics and presenters are identified by the Cases on the Web Board (COW) Board, a select group of experts in the management of HIV and other viral infections. Visit www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ for a list of COW Board members.

# CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS

The IAS-USA partners with the Conference on Retroviruses and Opportunistic Infections (CROI) Foundation to sponsor CROI, the most important HIV research conference worldwide. Webcasts, electronic posters, and abstracts from CROI 2014 to 2022 are available at www.CROIconference.org.

#### TOPICS IN ANTIVIRAL MEDICINE™

The IAS–USA publishes the peer-reviewed journal *Topics in Antiviral Medicine*<sup>™</sup> 4 to 6 times a year as a resource for physicians and other health care practitioners who are actively involved in the care of people with HIV or other viral infections. The journal offers CME credit and is indexed on *Index Medicus*/MEDLINE. Visit

https://www.iasusa.org/activities/topics-in-antiviral-medicine/current-issues/ to view the journal.

#### TREATMENT AND TESTING GUIDELINES

The IAS–USA sponsors the development of clinical practice guidelines. The guidelines are written by

independent volunteer panels of researchers and clinicians from around the world and focus on management issues for which definitive evidence is lacking. Guidelines for viral load testing, antiretroviral therapy, behavioral and biomedical HIV prevention, HIV drug resistance testing, cytomegalovirus infection, and metabolic complications have been published.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS-USA Antiretroviral Guidelines Panel, have been published in the *Journal of the American Medical Association*. Visit www.iasusa.org/resources/guidelines for updates.

Recommendations on the use of antiretroviral drugs for treatment and prevention of HIV infection in adults, by the IAS–USA Antiretroviral Guidelines Panel, were epublished in the *Journal of the American Medical Association* on October 14, 2020 (Saag MS, Gandhi RT, Hoy JF et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel. *JAMA*. 2020:E1-19). *JAMA* offers free access to the paper at

www.jamanetwork.com/journals/jama/fullarticle/277187

3. The paper includes updated recommendations for the use of antiretroviral therapy in adults with established HIV infection, including new recommendations on what regimens to start, updated approaches to prescribing preexposure prophylaxis (PrEP), new recommendations on management of aging among people with HIV, and overview of the then understanding of the intersection of COVID-19 disease and HIV.

#### **HIV DRUG RESISTANCE MUTATIONS**

Through the HIV Drug Resistance Mutations Panel, the IAS–USA provides regular updates on the mutations associated with resistance to antiretroviral drugs. A volunteer panel of acknowledged leaders in the field collect and review the information on relevant mutations. This information, last updated in July 2019, is available in *Topics in Antiviral Medicine*<sup>™</sup>, and on the IAS–USA website at www.iasusa.org/resources/hiv-drug-resistance-mutations/.

## COVID-19: WHAT WE KNOW TODAY. A DIALOGUE ABOUT THE PUBLIC HEALTH, SCIENTIFIC, AND CLINICAL ASPECTS OF THE PANDEMIC

The COVID-19 pandemic has created an urgent need for reliable scientific information. The IAS-USA COVID-19 Dialogues bring together 2 or more leading experts to discuss the latest science regarding COVID-19 and what the data and research are telling us about the basic science, public health, and clinical aspects of the disease, and the consequences of the pandemic.

Visit https://www.iasusa.org/activities/covid-19-dialogueseries/ for upcoming live Dialogues. The conversations are available on-demand as webcasts and podcasts after they are broadcast at

www.iasusa.org/activities/covid-19-dialogue-series/on-demand/.

#### **PODCASTS**

Many past IAS–USA activities are available as podcasts and may be downloaded from the IAS–USA website. Visit www.iasusa.org/resources/podcasts for details and a list of available presentations.

#### PRACTICE QUESTION OF THE WEEK

This new initiative started in 2021 and highlights updates to relevant practice guidelines or identified practice gaps. Each question is programmed as a popup and on the resources page on the IAS–USA website. Participants receive immediate feedback with the correct answer, explanation, and links to more resources. Visit https://www.iasusa.org/practice-question-of-the-week/ to view the most recent question and to see past questions.

#### **PRESENTATION SLIDES**

The IAS-USA offers a collection of downloadable presentation slides from various activities. Slides may be downloaded as PowerPoint files from the IAS-USA website at www.iasusa.org/resources/key-slides/.



For information about any of these programs, please visit www.IAS-USA.org.

Email: info@iasusa.org • Phone: (415) 544-9400